208 related articles for article (PubMed ID: 30663011)
1. Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.
Morino J; Hirai K; Kaneko S; Minato S; Yanai K; Mutsuyoshi Y; Ishii H; Matsuyama M; Kitano T; Shindo M; Aomatsu A; Miyazawa H; Ito K; Ueda Y; Hoshino T; Ookawara S; Hara K; Morishita Y
CEN Case Rep; 2019 May; 8(2):128-133. PubMed ID: 30663011
[TBL] [Abstract][Full Text] [Related]
2. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes.
Nonomura K; Iizuka K; Kuwabara-Ohmura Y; Yabe D
Intern Med; 2020 Jun; 59(12):1535-1539. PubMed ID: 32188813
[TBL] [Abstract][Full Text] [Related]
4. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
Imamura S; Hirai K; Hirai A
Tohoku J Exp Med; 2013 Sep; 231(1):57-61. PubMed ID: 24064677
[TBL] [Abstract][Full Text] [Related]
5. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
6. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
Goncalves E; Bell DSH
Diabetes Obes Metab; 2017 Jun; 19(6):909-911. PubMed ID: 28176440
[No Abstract] [Full Text] [Related]
8. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
[TBL] [Abstract][Full Text] [Related]
9. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
11. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Evans M; Bain SC; Hogan S; Bilous RW;
Nephrol Dial Transplant; 2012 Jun; 27(6):2255-63. PubMed ID: 22172728
[TBL] [Abstract][Full Text] [Related]
12. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Wanner C
Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
[No Abstract] [Full Text] [Related]
13. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Matos JP; de Lourdes Rodrigues M; Ismerim VL; Boasquevisque EM; Genelhu V; Francischetti EA
Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942
[TBL] [Abstract][Full Text] [Related]
14. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
15. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
16. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
Abdel-Wahab AF; Bamagous GA; Al-Harizy RM; ElSawy NA; Shahzad N; Ibrahim IA; Ghamdi SSA
Biomed Pharmacother; 2018 Jul; 103():59-66. PubMed ID: 29635129
[TBL] [Abstract][Full Text] [Related]
17. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Management of Diabetic Nephropathy.
Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
[TBL] [Abstract][Full Text] [Related]
19. Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
Ivory SE; Packham DK; Reutens AT; Wolfe R; Rohde RD; Lewis J; Atkins RC;
Nephrology (Carlton); 2013 Jul; 18(7):516-24. PubMed ID: 23506627
[TBL] [Abstract][Full Text] [Related]
20. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
Arai K; Morikawa Y; Ubukata N; Sugimoto K
Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
